SLS SELLAS Life Sciences Group Inc.: Earnings growth forecast for next year
The growth foundation of SELLAS Life Sciences (SLS) is based on a virtual cancer vaccine development model utilizing external contractors. The consensus EPS forecast for the coming year confirms this potential, where 53.60 records a new level. Management's strategy targets the fight against aggressive leukemia, and the sector's independence from macroeconomic factors transforms the asset into a resilient defensive tool.
Analytical breakdowns and data insights for company SELLAS Life Sciences Group (SLS)
- price and consensus price forecast:
- company stock capitalization data:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Total Debt to Capital SELLAS Life Sciences|SLS - Long-Term Debt to Capital|Short-Term Debt to Equity SELLAS Life Sciences Group, Inc.|SLS - Company Total Debt Obligations|Debt to Book Value SELLAS Life Sciences|SLS - Company Long-Term Loans and Borrowings|Company Short-Term Debt SELLAS Life Sciences|Quick Ratio sellaslifesciences.com
- net income and valuation ratios data:
SLS - Net Financial Result|Projected Future Earnings SELLAS Life Sciences|SLS - Market Cap to Net Income|Forward P/E Multiple SELLAS Life Sciences Group, Inc.|SLS - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio SELLAS Life Sciences|SLS - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months SELLAS Life Sciences|SLS - Net earnings per share for the last four quarters|Quarterly EPS earnings growth sellaslifesciences.com|SLS - Net earnings per share growth this year|Earnings growth forecast for next year SELLAS Life Sciences
Initial company analysis:SELLAS Life Sciences
A defensive portfolio requires a strict filter for future return potential. This indicator measures the percentage change in expected earnings per share (EPS), neutralizing inflationary noise by comparing it with historical data. For SELLAS Life Sciences (SLS), this metric reflects the probability of commercial success for leukemia vaccines following the completion of clinical phases. By analyzing analysts' 12-month EPS growth targets, an investor can determine the risk of asset overvaluation.
Competitor analysis for SELLAS Life Sciences
Net earnings per share growth forecast for next year BeiGene Corp|Halozyme Corp (HALO) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year RVMD|AAPG - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year CG Oncology CGON|UroGen Pharma Ltd - Net earnings per share growth forecast for next year|BCAX - Net earnings per share growth forecast for next year|PSNL: Net earnings per share growth forecast for next year|ERAS: Earnings growth forecast for next year|delcath.com (DCTH) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Y-mAbs Therapeutics, Inc.|Aura Biosciences Inc (AURA) - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year CADL (Candel Therapeutics)|ARAY (Accuray, Inc.) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Actuate Therapeutics, Inc. ACTU|citiusonc.com - Net earnings per share growth forecast for next year|TuHURA - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Protara Therapeutics Inc TARA|FATE: Earnings growth forecast for next year|Net earnings per share change forecast for next year WHWK (Aadi Bioscience)|TCRX (TScan Therapeutics Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year Champions Oncology Corp CSBR|Expected earnings per share growth for next year XBIT (XBiotech Inc.)|CVM (cel-sci.com) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year OS Therapies Inc OSTX|Consensus forecast of earnings per share growth for next year radiopharmtheranostics.com (RADX)|Artiva - Earnings growth forecast for next year|Adlai Nortye Ltd. (ANL) - Expected earnings per share growth for next year|VERU: Earnings growth forecast for next year|TPST - Consensus forecast of earnings per share growth for next year|XLO (Xilio Therapeutics Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year Enochian BioSciences RENB|Net earnings per share growth forecast for next year Mural Oncology plc (MURA)|kairospharma.com - Projected earnings per share growth rate for next year|Earnings growth forecast for next year OKUR (OnKure Therapeutics)|GDTC - Expected earnings per share growth for next year|Curis Corp - Earnings growth forecast for next year|Expected net earnings per share growth next year Apollomics, Inc.|Tharimmune, Inc. (THAR) - Net earnings per share growth forecast for next year|ADVB - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Genprex|Calidi Bio (CLDI) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Sunshine Biopharma, Inc. (SBFM)|Net earnings per share growth forecast for next year XBIO (xeneticbio.com)|Net earnings per share growth forecast for next year Salarius Pharmaceuticals SLRX|Consensus forecast of earnings per share growth for next year purple-biotech.com (PPBT)|AON - Earnings growth forecast for next year|BeiGene Ltd. (BGNE) - Expected earnings per share growth for next year|CKPT: Earnings growth forecast for next year|elevationoncology.com (ELEV) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year iCAD Inc.|Projected earnings per share growth rate for next year IKNA (Ikena)|Earnings growth forecast for next year NTBL|Expected earnings per share growth for next year viracta.com VIRX|Earnings growth forecast for next year MOR (MorphoSys Corp)|NAYA Biosciences Corp (NAYA) - Expected net earnings per share growth next year|AAPGV - Net earnings per share growth forecast for next year
